Scotiabank Cuts Kura Oncology (NASDAQ:KURA) Price Target to $10.00

Kura Oncology (NASDAQ:KURA - Free Report) had its target price cut by Scotiabank from $18.00 to $10.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a sector perform rating on the stock.

KURA has been the subject of several other reports. Stifel Nicolaus downgraded Kura Oncology from a "buy" rating to a "hold" rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, October 22nd. JMP Securities reiterated a "market outperform" rating and set a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. UBS Group began coverage on Kura Oncology in a report on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $27.38.

Kura Oncology Trading Down 4.8 %

Shares of KURA traded down $0.39 during mid-day trading on Wednesday, reaching $7.78. The company had a trading volume of 2,097,310 shares, compared to its average volume of 1,500,170. Kura Oncology has a fifty-two week low of $7.70 and a fifty-two week high of $24.17. The firm has a fifty day simple moving average of $12.11 and a 200-day simple moving average of $17.08. The stock has a market cap of $605.00 million, a price-to-earnings ratio of -3.30 and a beta of 0.81. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KURA. Suvretta Capital Management LLC raised its stake in shares of Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Armistice Capital LLC raised its stake in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after buying an additional 302,000 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after acquiring an additional 41,535 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock worth $28,687,000 after acquiring an additional 23,113 shares in the last quarter. Finally, Sofinnova Investments Inc. increased its holdings in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company's stock valued at $16,992,000 after acquiring an additional 323,303 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.